ArticleCells2020
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation.Endocrine-related cancer · 2025Article
- Development and preliminary validation of five miRNAs for lung adenocarcinoma prognostic model associated with immune infiltration.Scientific reports · 2025Article
- Article
- Review
- Post-Transcriptional Modifications to miRNAs Undergo Widespread Alterations, Creating a Unique Lung Adenocarcinoma IsomiRome.Cancers · 2024Article
- Identification of Tumor SuppressiveInternational journal of molecular sciences · 2024Article
- A study of microRNAs as new prognostic biomarkers in anal cancer patients.Acta oncologica (Stockholm, Sweden) · 2024Article
- Wemics: A Single-Base Resolution Methylation Quantification Method for Enhanced Prediction of Epigenetic Regulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Minichromosome maintenance proteins in lung adenocarcinoma: Clinical significance and therapeutic targets.FEBS open bio · 2023Article
- Cell Cycle-Related FAM64A Could be Activated by TGF-β Signaling to Promote Glioma Progression.Cellular and molecular neurobiology · 2023Article
- The Molecular Pathogenesis of Tumor-SuppressiveCells · 2023Article
- Targeting mitochondrial one-carbon enzyme MTHFD2 together with pemetrexed confers therapeutic advantages in lung adenocarcinoma.Cell death discovery · 2022Article
- FAM64A promotes HNSCC tumorigenesis by mediating transcriptional autoregulation of FOXM1.International journal of oral science · 2022Article
- Identification and evaluation of circulating small extracellular vesicle microRNAs as diagnostic biomarkers for patients with indeterminate pulmonary nodules.Journal of nanobiotechnology · 2022Article
- Identification of Tumor-SuppressiveInternational journal of molecular sciences · 2022Article
- Multi-omics data integration for subtype identification of Chinese lower-grade gliomas: A joint similarity network fusion approach.Computational and structural biotechnology journal · 2022Article
- A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma.Clinical and translational medicine · 2021Article
- Article
- Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role.Frontiers in genetics · 2021Article
- Regulation of Oncogenic Targets by the Tumor-SuppressiveBiomedicines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) is the most aggressive cancer and the prognosis of these patients is unfavorable. We revealed that the expression levels of both strands of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.